Novavax in the spotlight (part V)

Analyzing $NVAX in light of the Covid delta variant

Following up on our newsletter coverage of Novavax (see our Boutique Biotech archive for parts I-IV), here we cover the Covid delta variant. Over the past few months, the delta variant has been making more and more waves, and several countries are voicing their concerns. Below we look at the data and determine if the high alert is justified for this la…